Zhao et al. took the initiative of conducting the direct comparison of intraductal carcinoma of the prostate (IDC-P) and adenocarcinoma, by manually dissecting IDC-P from adenocarcinoma, followed by IHC validation, WES, RNA-seq and methylation sequencing [1]. It showed many interesting and new findings of IDC-P which are possibly underscored when previous researchers are using tumor mixtures as their IDC-P-containing model. Many of the findings here can help to explain the demonstrated aggressiveness of IDC-P and its worse responses to standard therapy. Certain results such as the enhanced cellular proliferation and intratumorally androgen biosynthesis can potentially enlighten future targeted therapies in this group of patients.

The study not only highlights IDC-P’s unique characteristics but also emphasizes the importance of nuanced investigations in prostate cancer. Precision medicine requires a relentless commitment to understanding subtypes like IDC-P, ensuring targeted interventions that consider the specific molecular intricacies of each patient’s cancer journey.

赵等人。率先开展了前列腺导管内癌（IDC-P）和腺癌的直接比较，通过手动解剖腺癌中的IDC-P，然后进行IHC验证、WES、RNA-seq和甲基化测序[1]。它显示了 IDC-P 的许多有趣的新发现，当以前的研究人员使用肿瘤混合物作为含有 IDC-P 的模型时，这些发现可能会得到强调。这里的许多发现可以帮助解释 IDC-P 所表现出的侵袭性及其对标准治疗的较差反应。某些结果，例如增强的细胞增殖和瘤内雄激素生物合成，可能会启发该组患者未来的靶向治疗。

该研究不仅强调了 IDC-P 的独特特征，还强调了对前列腺癌进行细致入微研究的重要性。精准医学需要不懈地致力于了解 IDC-P 等亚型，确保有针对性的干预措施考虑到每位患者癌症历程的特定分子复杂性。